Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

PHASE3CompletedINTERVENTIONAL
Enrollment

1,003

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Alzheimer's Disease
Interventions
DRUG

Dimebon

5 mg orally three times daily

DRUG

Dimebon

20 mg orally three times daily

DRUG

Placebo comparator

Placebo orally three times daily

Trial Locations (101)

10029

New York

11516

Cedarhurst

12208

Albany

14620

Rochester

19046

Jenkintown

19401

Norristown

20057

Washington D.C.

21601

Eaton

22903

Charlottesville

27710

Durham

30329

Atlanta

32224

Jacksonville

32806

Orlando

33064

Deerfield Beach

33137

Miami

33445

Delray Beach

40536

Lexington

43623

Toledo

44122

Beachwood

46260

Indianapolis

48105

Ann Arbor

53562

Middleton

77030

Houston

78229

San Antonio

78757

Austin

80218

Denver

80304

Boulder

85006

Phoenix

85351

Sun City

85724

Tucson

89106

Las Vegas

90095

Los Angeles

90720

Los Alamitos

90723

Paramount

91105

Pasadena

91316

Encino

92025

Escondido

92037

La Jolla

92103

San Diego

92626

Costa Mesa

92660

Newport

92845

Garden Grove

93720

Fresno

94143

San Francisco

94553

Martinez

96814

Honolulu

98108

Seattle

06510

New Haven

02118

Boston

07865

Mount Arlington

08540

Princeton

02906

Providence

Unknown

Newcastle

Sydney

Brisbane

Adelaide

Geelong

Melbourne

Perth

Antwerp

Leuven

Sint-Truiden

Kuppio

Oulu

Turku

Bordeaux

Concert

Lille

Montpellier

Nice

Toulouse

Berlin

Bochum

Freiburg im Breisgau

Hattingen

Mannheim

Munich

Brescia

Florence

Genoa

Perugia

Rome

Christchurch

Auckland

Malmo

Norrköping

Stockholm

Brentford

Rushden

Glasgow

Worthington

Bath

Blackpool

Bradford

Greater Manchester

London

Newcastle upon Tyne

Norfolk

Oxford

Southampton

Swindon

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Medivation, Inc.

INDUSTRY